Funding for Interactive Event to Further Clinician Understanding of the Role of Fatigue in Depression
CHALFONT, PA – May 24, 2012 – Genomind, LLC., is dedicated to furthering personalized medicine and has awarded an educational grant to provide partial support for the MGH Psychiatry Academy’s development of a new, learning symposia for clinicians. The Psychiatry Academy’s interactive live learning event, “The Role of Fatigue in Depressive Disorders & Using Biomarkers for Personalized Treatment” will take place on June 2, 2012 at The Liberty Hotel in Boston, and on June 9, 2012 at the Westin Michigan Avenue, Chicago. The events are also offered online for a year after the live event.
This interactive program will define and examine the many manifestations and ramifications of fatigue in depression. Participants will learn to define the multifactorial symptom domains of fatigue, identify the role of fatigue in the prodromal, acute and maintenance phases of depression, and employ cutting-edge psychopharmacologic strategies to minimize the occurrence and adverse consequences of fatigue. The program will also educate clinicians about the current role of biomarkers in psychiatry, and the increased interest in the clinical application of psychiatric biomarkers.
“Genomind is pleased to provide partial support for educational initiatives from an institution like MGH, where professionals can access world-renowned education that will further the potential application of personalized medicine in psychiatry,” said Jay Lombard, DO, Chief Scientific Officer and Medical Director for Genomind.
Designed in accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, this live activity is designated for a maximum of 8AMA PRA Category 1 CreditsTM, depending on extent of participation.
Clinicians may learn more and register for the MGH symposium by visiting>:http://mghacademy.org/.
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders, and supports many initiatives that further the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.
For more information, contact:
Marketing Manager, Genomind